Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Rosenberg JE, et al. Among authors: bourgon r. Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4. Lancet. 2016. PMID: 26952546 Free PMC article. Clinical Trial.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Balar AV, et al. Among authors: bourgon r. Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Lancet. 2017. PMID: 27939400 Free PMC article. Clinical Trial.
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T. Mariathasan S, et al. Among authors: bourgon r. Nature. 2018 Feb 22;554(7693):544-548. doi: 10.1038/nature25501. Epub 2018 Feb 14. Nature. 2018. PMID: 29443960 Free PMC article.
Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets.
Bolen CR, McCord R, Huet S, Frampton GM, Bourgon R, Jardin F, Dartigues P, Punnoose EA, Szafer-Glusman E, Xerri L, Sujobert P, Salles G, Venstrom JM. Bolen CR, et al. Among authors: bourgon r. Blood Adv. 2017 Sep 27;1(22):1884-1890. doi: 10.1182/bloodadvances.2016000786. eCollection 2017 Oct 10. Blood Adv. 2017. PMID: 29296835 Free PMC article.
Peripheral T cell expansion predicts tumour infiltration and clinical response.
Wu TD, Madireddi S, de Almeida PE, Banchereau R, Chen YJ, Chitre AS, Chiang EY, Iftikhar H, O'Gorman WE, Au-Yeung A, Takahashi C, Goldstein LD, Poon C, Keerthivasan S, de Almeida Nagata DE, Du X, Lee HM, Banta KL, Mariathasan S, Das Thakur M, Huseni MA, Ballinger M, Estay I, Caplazi P, Modrusan Z, Delamarre L, Mellman I, Bourgon R, Grogan JL. Wu TD, et al. Among authors: bourgon r. Nature. 2020 Mar;579(7798):274-278. doi: 10.1038/s41586-020-2056-8. Epub 2020 Feb 26. Nature. 2020. PMID: 32103181
Reproducible pharmacogenomic profiling of cancer cell line panels.
Haverty PM, Lin E, Tan J, Yu Y, Lam B, Lianoglou S, Neve RM, Martin S, Settleman J, Yauch RL, Bourgon R. Haverty PM, et al. Among authors: bourgon r. Nature. 2016 May 19;533(7603):333-7. doi: 10.1038/nature17987. Nature. 2016. PMID: 27193678
Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy.
Dominguez CX, Müller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, Breart B, Foreman O, Bainbridge TW, Castiglioni A, Senbabaoglu Y, Modrusan Z, Liang Y, Junttila MR, Klijn C, Bourgon R, Turley SJ. Dominguez CX, et al. Among authors: bourgon r. Cancer Discov. 2020 Feb;10(2):232-253. doi: 10.1158/2159-8290.CD-19-0644. Epub 2019 Nov 7. Cancer Discov. 2020. PMID: 31699795
Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.
Qu X, Sandmann T, Frierson H Jr, Fu L, Fuentes E, Walter K, Okrah K, Rumpel C, Moskaluk C, Lu S, Wang Y, Bourgon R, Penuel E, Pirzkall A, Amler L, Lackner MR, Tabernero J, Hampton GM, Kabbarah O. Qu X, et al. Among authors: bourgon r. Oncogene. 2016 Dec 15;35(50):6403-6415. doi: 10.1038/onc.2016.170. Epub 2016 Jun 6. Oncogene. 2016. PMID: 27270421 Free PMC article.
Reply to T.J. Kruser et al.
Chinot OL, Taphoorn MJ, Bais C, Bourgon R, Phillips HS, Abrey LE, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Cloughesy T. Chinot OL, et al. Among authors: bourgon r. J Clin Oncol. 2016 Apr 10;34(11):1282-3. doi: 10.1200/JCO.2015.65.2438. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884575 No abstract available.
56 results